Key result
Metoprolol formulations, including extended-release and immediate-release forms, are reviewed for their efficacy, safety, and pharmacoeconomic impacts in treating cardiovascular diseases.
This review discusses the efficiency, safety, and pharmacoeconomics of different formulations of metoprolol in cardiovascular diseases.
Does not support changes in metoprolol prescribing; leaves open need for comparative trials on formulation outcomes.
Metoprolol treatment in cardiovascular diseases is discussed considering efficiency, safety and pharmacoeconomic aspects. The article reviews the main clinical trials of metoprolol and its different forms (Extended-Release and Immediate-Release metoprolol, tartrate and succinate).
No takes yet. Share an insight, caveat, or question.
Э. В. Кулешова (2009) studied this question. Metoprolol formulations, including extended-release and immediate-release forms, are reviewed for their efficacy, safety, and pharmacoeconomic impacts in treating cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: